Stanley C. Erck - Sep 26, 2022 Form 4 Insider Report for NOVAVAX INC (NVAX)

Role
President and CEO, Director
Signature
/s/ John A. Herrmann III, Attorney-in-Fact
Stock symbol
NVAX
Transactions as of
Sep 26, 2022
Transactions value $
-$41,137
Form type
4
Date filed
9/28/2022, 05:02 PM
Previous filing
Jul 8, 2022
Next filing
Dec 16, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NVAX Common Stock Options Exercise +6.55K +23.82% 34K Sep 26, 2022 Direct F1
transaction NVAX Common Stock Tax liability -$41.1K -2.18K -6.41% $18.87 31.8K Sep 26, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NVAX Restricted Stock Units Options Exercise $0 -6.55K -100% $0.00* 0 Sep 26, 2022 Common Stock 6.55K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.
F2 The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the September 26, 2019 grant date, in each case subject to continued employment through such vesting date.